Certified by Founder Lodge 
                                        
                                        Alexandria Real Estate Equities, Inc.
 
                                                 United States  -  Pasadena, California 
                                             INVESTOR 
                                            
                                                                                    1 Disclosed Funding Rounds $100,000,000
                                            60 Participating Investments
- 
                                                Operating Status 
                                                
Active
 - 
                                                Last Funding Type 
                                                
Seed
 - 
                                                Company Type 
                                                
For Profit
 - Website
 - Contact
 - Social Links
 
                                            Alexandria Real Estate Equities, Inc. (NYSE:ARE), an S&P 500® urban office real estate investment trust (REIT), pioneered the life science real estate niche and remains the longest-tenured ow
                                        
                                        
                                        
                                                                                
                                        
                                        
                                        
                                        
                                                                                
                                        | Company | Date | Round | Raised | 
|---|---|---|---|
   Boundless Bio | 
                                                            May, 17 ,2023 | Series C | $100,000,000 | 
   Delphia Therapeutics | 
                                                            May, 07 ,2024 | Series A | $67,000,000 | 
   Leal Therapeutics | 
                                                            October, 31 ,2024 | Unknown | $45,000,000 | 
   Matchpoint Therapeutics | 
                                                            October, 17 ,2022 | Series A | $100,000,000 | 
   Ensoma | 
                                                            February, 06 ,2023 | Series B | $85,000,000 | 
   Solu Therapeutics | 
                                                            August, 01 ,2023 | Seed | $31,000,000 | 
   TwoStep Therapeutics | 
                                                            June, 26 ,2024 | Seed | $6,500,000 | 
   CrossBridge Bio | 
                                                            November, 05 ,2024 | Unknown | $10,000,000 | 
   Function Oncology | 
                                                            April, 13 ,2023 | Series A | $28,000,000 | 
   Georgiamune Inc. | 
                                                            August, 10 ,2023 | Series A | $75,000,000 | 
   Outpace Bio | 
                                                            August, 02 ,2024 | Series B | $144,000,000 | 
   Umoja Biopharma | 
                                                            January, 21 ,2025 | Series C | $100,000,000 | 
   Orbital Therapeutics | 
                                                            April, 27 ,2023 | Unknown | $270,000,000 | 
   Alto Neuroscience | 
                                                            November, 22 ,2023 | Series C | $45,000,000 | 
   Archon Biosciences | 
                                                            October, 31 ,2024 | Seed | $20,000,000 | 
   Remedy Plan Therapeutics | 
                                                            May, 14 ,2025 | Unknown | $18,000,000 | 
   Boundless Bio | 
                                                            May, 17 ,2023 | Series C | $100,000,000 | 
   Odyssey Therapeutics | 
                                                            December, 06 ,2023 | Series C | $101,000,000 | 
   Leal Therapeutics | 
                                                            October, 31 ,2024 | Unknown | $45,000,000 | 
   Ability Biologics | 
                                                            December, 07 ,2023 | Seed | $12,000,000 | 
   Solu Therapeutics | 
                                                            August, 01 ,2023 | Seed | $31,000,000 | 
   Tome Biosciences | 
                                                            December, 14 ,2023 | Series B | $213,000,000 | 
   CrossBridge Bio | 
                                                            November, 05 ,2024 | Unknown | $10,000,000 | 
   Remix Therapeutics | 
                                                            January, 04 ,2024 | Unknown | $60,000,000 | 
   Georgiamune Inc. | 
                                                            August, 10 ,2023 | Series A | $75,000,000 | 
   Tr1X | 
                                                            January, 19 ,2024 | Series A | $75,000,000 | 
   Umoja Biopharma | 
                                                            January, 21 ,2025 | Series C | $100,000,000 | 
   Elo Life Systems | 
                                                            January, 25 ,2024 | Series A | $20,500,000 | 
   Alto Neuroscience | 
                                                            November, 22 ,2023 | Series C | $45,000,000 | 
   Capstan Therapeutics | 
                                                            March, 21 ,2024 | Series B | $175,000,000 | 
   Remedy Plan Therapeutics | 
                                                            May, 14 ,2025 | Unknown | $18,000,000 | 
   Mirador Therapeutics | 
                                                            March, 26 ,2024 | Unknown | $400,000,000 | 
   Odyssey Therapeutics | 
                                                            December, 06 ,2023 | Series C | $101,000,000 | 
   OverT Bio | 
                                                            May, 07 ,2024 | Seed | $16,000,000 | 
   Ability Biologics | 
                                                            December, 07 ,2023 | Seed | $12,000,000 | 
   Delphia Therapeutics | 
                                                            May, 07 ,2024 | Series A | $67,000,000 | 
   Tome Biosciences | 
                                                            December, 14 ,2023 | Series B | $213,000,000 | 
   TwoStep Therapeutics | 
                                                            June, 26 ,2024 | Seed | $6,500,000 | 
   Remix Therapeutics | 
                                                            January, 04 ,2024 | Unknown | $60,000,000 | 
   Outpace Bio | 
                                                            August, 02 ,2024 | Series B | $144,000,000 | 
   Tr1X | 
                                                            January, 19 ,2024 | Series A | $75,000,000 | 
   Archon Biosciences | 
                                                            October, 31 ,2024 | Seed | $20,000,000 | 
   Elo Life Systems | 
                                                            January, 25 ,2024 | Series A | $20,500,000 | 
   Leal Therapeutics | 
                                                            October, 31 ,2024 | Unknown | $45,000,000 | 
   Capstan Therapeutics | 
                                                            March, 21 ,2024 | Series B | $175,000,000 | 
   CrossBridge Bio | 
                                                            November, 05 ,2024 | Unknown | $10,000,000 | 
   Mirador Therapeutics | 
                                                            March, 26 ,2024 | Unknown | $400,000,000 | 
   Umoja Biopharma | 
                                                            January, 21 ,2025 | Series C | $100,000,000 | 
   OverT Bio | 
                                                            May, 07 ,2024 | Seed | $16,000,000 | 
   Remedy Plan Therapeutics | 
                                                            May, 14 ,2025 | Unknown | $18,000,000 | 
   Delphia Therapeutics | 
                                                            May, 07 ,2024 | Series A | $67,000,000 | 
   Affinia Therapeutics | 
                                                            October, 10 ,2025 | Series C | $40,000,000 | 
   TwoStep Therapeutics | 
                                                            June, 26 ,2024 | Seed | $6,500,000 | 
   Outpace Bio | 
                                                            August, 02 ,2024 | Series B | $144,000,000 | 
   Archon Biosciences | 
                                                            October, 31 ,2024 | Seed | $20,000,000 | 
   Leal Therapeutics | 
                                                            October, 31 ,2024 | Unknown | $45,000,000 | 
   CrossBridge Bio | 
                                                            November, 05 ,2024 | Unknown | $10,000,000 | 
   Umoja Biopharma | 
                                                            January, 21 ,2025 | Series C | $100,000,000 | 
   Remedy Plan Therapeutics | 
                                                            May, 14 ,2025 | Unknown | $18,000,000 | 
   Affinia Therapeutics | 
                                                            October, 10 ,2025 | Series C | $40,000,000 | 
                                                
  Boundless Bio
  Delphia Therapeutics
  Leal Therapeutics
  Matchpoint Therapeutics
  Ensoma
  Solu Therapeutics
  TwoStep Therapeutics
  CrossBridge Bio
  Function Oncology
  Georgiamune Inc.
  Outpace Bio
  Umoja Biopharma
  Orbital Therapeutics
  Alto Neuroscience
  Archon Biosciences
  Remedy Plan Therapeutics
  Odyssey Therapeutics
  Ability Biologics
  Tome Biosciences
  Remix Therapeutics
  Tr1X
  Elo Life Systems
  Capstan Therapeutics
  Mirador Therapeutics
  OverT Bio
  Affinia Therapeutics
Properly
 
                                            
Nabr
Mudafy
 
                                            
Latchel
Casavo
 
                                            
                                                                        
                                Helex |  $3,500,000  | (Nov 4, 2025)
                                                                        
                                xMEMS |  $21,000,000  | (Nov 4, 2025)
                                                                        
                                catalyx space |  $5,400,000  | (Nov 4, 2025)
                                                                        
                                Cephia AI |  $4,000,000  | (Nov 4, 2025)
                                                                        
                                Ornn |  $5,700,000  | (Nov 4, 2025)